Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax

BACKGROUND: The BCL2 inhibitor venetoclax has shown efficacy in several hematologic malignancies, with the greatest response rates in indolent blood cancers such as chronic lymphocytic leukaemia. There is a lower response rate to venetoclax monotherapy in diffuse large B-cell lymphoma (DLBCL). METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Herzog, Lee-or, Walters, Beth, Buono, Roberta, Lee, J. Scott, Mallya, Sharmila, Fung, Amos, Chiu, Honyin, Nguyen, Nancy, Li, Boyang, Pinkerton, Anthony B., Jackson, Michael R., Schneider, Robert J., Ronai, Ze’ev A., Fruman, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960756/
https://www.ncbi.nlm.nih.gov/pubmed/33318657
http://dx.doi.org/10.1038/s41416-020-01205-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960756/
https://www.ncbi.nlm.nih.gov/pubmed/33318657
http://dx.doi.org/10.1038/s41416-020-01205-9

Ejemplares similares